Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MD1003 (high-dose biotin) on chronic visual loss after optic neuritis in multiple sclerosis
2013-002112-27Phase 3Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS), optic neuritis (ON) and Visual Impairment (VI) comparing MD1003 (biotin 300 mg/day) with Placebo (2 arms). Primary endpoint: Change in best corrected visual acuity at 6 months. Started May 2015; status: completed.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)optic neuritis (ON)Visual Impairment (VI)
Beyond the preview
Go deeper on 2013-002112-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002112-27.